• Pancho trial (p53-adapted neoadjuvant chemotherapy for resectable esophageal cancer) completed-mutation rate of the marker higher than expected
• Pancho试验(针对可切除食管癌的p53靶向新辅助化疗)已完成,但该标志物的突变率高于预期。
期刊:European Surgery-Acta Chirurgica Austriaca
影响因子:0.8
doi:10.1007/s10353-018-0527-z
Kappel-Latif, Sonja; Zacherl, Johannes; Hejna, Michael; Westerhoff, Maria; Tamandl, Dietmar; Ba-Ssalamah, Ahmed; Mittlböck, Martina; Wolf, Brigitte; Wrba, Friedrich; Kührer, Irene; Pluschnig, Ursula; Schoppmann, Sebastian F; Függer, Reinhold; Zwrtek, Ronald; Glaser, Karl; Karner, Josef; Längle, Friedrich; Wenzl, Etienne; Roka, Rudolf; Öfner, Dietmar; Tschmelitsch, Jörg; Hold, Michael; Keil, Felix; Gnant, Michael; Kandioler, Daniela